Cargando…
Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. Following recent regulatory approvals in the USA and European Union, IFN beta-1b is...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177103/ https://www.ncbi.nlm.nih.gov/pubmed/25182864 http://dx.doi.org/10.1007/s12325-014-0149-1 |